Im­mat­ics spot­lights more ear­ly da­ta for TCR cell ther­a­py in sol­id tu­mors — now let's see if it lasts

Al­most a year af­ter Im­mat­ics first took the wraps off pre­lim­i­nary da­ta for its top TCR cell ther­a­py, the biotech says the drug con­tin­ues to live up to ex­pec­ta­tions.

Now that the Phase Ia dose es­ca­la­tion study is com­plete, Im­mat­ics has treat­ed five pa­tients with IMA203 in the Phase Ib at what it be­lieves is the op­ti­mal dose, com­plete with im­proved man­u­fac­tur­ing and study de­sign.

And that, ac­cord­ing to the biotech, boost­ed the con­firmed ob­jec­tive re­sponse rate to 80% — which, if sus­tained, would mark a land­mark suc­cess for the quest to de­vel­op cell ther­a­pies for sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER